Could inflammation predict who benefits from magic mushroom therapy?
NCT ID NCT07164755
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study examines blood samples from 46 people with treatment-resistant depression who took psilocybin in a previous trial. Researchers will measure markers of inflammation (cytokines and mRNA) to see if they relate to how well the treatment worked. The goal is to understand whether inflammation levels before or after treatment can predict who gets better, which could help personalize psychedelic therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors predict who will benefit from psilocybin therapy and point toward new ways to treat depression by targeting inflammation.
What could go wrong
This is a small, observational analysis of existing samples, not a new treatment trial. It may not find clear links between inflammation and depression outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSION - MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
King's College London Institute of Psychiatry, Psychology and Neuroscience
London, SE5 8AF, United Kingdom